Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01180868 · ClinicalTrials.gov registry record

The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases

A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.

Completed
Registry status
1
Enrollment target

NCT01180868 is a clinical trial that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01180868 has completed, sponsored by Jonsson Comprehensive Cancer Center.

COMPLETED
Registry status
1 participants
Enrollment target

Study Summary

The purpose of this study is to determine the biodistribution of a new agent 1-L-(2 deoxy-2,-18fluoroarabinofuranosyl) cytosine non-invasively in healthy humans and to evaluate whether it can be used to image cancer, autoimmune disease, and inflammation

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2008-05

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

What the Registry Record Tells You About NCT01180868

The ClinicalTrials.gov registry entry for NCT01180868 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01180868 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01180868 about?

NCT01180868 is a clinical study titled "The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases". The purpose of this study is to determine the biodistribution of a new agent 1-L-(2 deoxy-2,-18fluoroarabinofuranosyl) cytosine non-invasively in healthy humans and to evaluate whether it can be used to image cancer, autoimmune disease, and inflammation

What is the current status of trial NCT01180868?

This trial is currently completed. The enrollment target is 1 participants. The study started on 2008-05.

Who is sponsoring clinical trial NCT01180868?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.